Back to School: How biopharma can reboot drug development. Access exclusive analysis here

The Fuji-Yama merger

The Fuji-Yama merger

Product Indication Status Company Partner Rights (A)
Vesicare solifenacin (YM905) Overactive bladder (OAB) Marketed (EU); approvable letter (U.S.) Yamanouchi GlaxoSmithKline U.S. co-promotion rights
TRK-820 Dialysis-related uremic pruritis

Read the full 324 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE